Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22732727 | 1.00 | HRH3 (0.42) | HRH3HTR4CHEK1EPHA2KDR | |
| Hydrochloric Acid SCHEMBL30133730 | 0.98 | HRH3 (0.41) | HRH3HTR4CHEK1EPHA2KDR | |
| SCHEMBL22732596 | 0.84 | HRH3 (0.35) | HRH3CHEK1CHEK2 | |
| SCHEMBL1958518 | 0.84 | HRH3 (0.35) | HRH3CHEK1CHEK2 | |
| SCHEMBL23710030 | 0.82 | HRH3 (0.47) | HRH3HTR4EPHA2KDRCCR2 | |
| SCHEMBL25481527 | 0.79 | CHEK1 (0.35) | HRH3CHEK1CHEK2 | |
| SCHEMBL22732893 | 0.78 | HTR4 (0.43) | HRH3HTR4EPHA2KDRCCR2 | |
| SCHEMBL28563996 | 0.78 | CHEK1 (0.34) | HRH3CHEK1CHEK2 | |
| SCHEMBL24627203 | 0.76 | HTR4 (0.42) | HRH3HTR4EPHA2KDR | |
| SCHEMBL12331474 | 0.76 | HRH3 (0.33) | HRH3ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257064-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| US-12371431-B2 | Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| CN-116199686-A | Trifluoromethyl substituted sulfonamide compounds | 正大天晴药业集团股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-112888687-B | Trifluoromethyl substituted sulfonamides selective BCL-2 inhibitors | 正大天晴药业集团股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20220220110-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3858832-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858832-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| CN-112888687-A | Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors | 正大天晴药业集团股份有限公司 | 2021-06-01 | — | — | CN | disclosed |
| WO-2020238785-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | 正大天晴药业集团股份有限公司 | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002290-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | BCL2L11, BCL2, BCL2L2 | HRH3 4374/4885HTR4 4176/4885CHEK1 3675/4885 |
| US-20220220110-A1 | METHYL- AND TRIFLUOROMETHYL-CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | BCL2L11, BCL2, BCL2L1 | HRH3 4603/4885HTR4 4376/4885CHEK1 3602/4885 |
| US-12371431-B2 | Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor | BCL2L11, BCL2, BCL2L2 | HRH3 4374/4885HTR4 4176/4885CHEK1 3675/4885 |
| US-20250257064-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | BCL2, BAX, BCL2L2 | HRH3 4099/4885HTR4 4488/4885CHEK1 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.